Authors

Latest:

Cemiplimab Monotherapy for First Line Advanced NSCLC Patients With PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung

Dr. Garassino presents 5-year results from the EMPOWER-Lung 1 trial, discussing cemiplimab monotherapy's long-term survival benefits in advanced NSCLC patients with PD-L1 expression ≥50%.

Marina Garassino, MD National Cancer Institute

Marina Garassino, MD, National Cancer Institute Milan, Italy

Marina Garassino, MD, National Cancer Institute of Milan

Marina Kremyanskaya, MD

Latest:

Dr. Kremyanskaya on the Need for Disease-Modifying Approaches in MPNs

Marina Kremyanskaya, MD, PhD, discusses the need for disease-modifying treatment approaches for patients with myeloproliferative neoplasms.

Marina Kremyanskaya, MD, PhD

Latest:

Dr Kremyanskaya on the Use of Cytoreductive Measures in PV and ET

Marina Kremyanskaya, MD, PhD, discusses disease and patient characteristics that influence the choice between hydroxyurea and interferon therapy for patients with polycythemia vera or essential thrombocythemia.

Mario E. Lacouture, MD

Latest:

Dr. Lacouture On Preventing Dermatological Adverse Events in Melanoma

Mario E. Lacouture, MD, a dermatologist with Memorial Sloan Kettering Cancer Center, explains how providers can manage adverse events that result from melanoma therapies.

Mario M. Leitao Jr, MD, FACOG, FACS

Latest:

Dr. Leitao Discusses the Role of HIPEC in Advanced Ovarian Cancer

Mario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the role of HIPEC in patients with advanced ovarian cancer.

Mario Sznol, MD

Latest:

Dr. Sznol on the Significance of the Relatlimab/Nivolumab Approval in Metastatic Melanoma

Mario Sznol, MD, explains the evaluation of efficacy and safety when examining the benefits of new immunotherapy combinations in cancer.

Marissa Murtaugh

Latest:

Poster Session Highlights: 12th International Lung Cancer Congress

A highlight of 3 poster sessions from the 12th International Lung Cancer Congress on August 12, 2011 in Carlsbad, CA.

Mark A. Morgan, MD

Latest:

Dr. Morgan on Bulk Reduction Surgery in Ovarian Cancer

Mark A. Morgan, MD, professor of obstetrics and gynecology, University of Pennsylvania, director, Gynecology Oncology for University of Pennsylvania Health Systems, discusses bulk reduction surgery prior to chemotherapy in patients with stage III ovarian cancer.

Mark A. Rubin, MD

Latest:

Dr. Rubin on Advantages With Whole-Exome Sequencing

Mark A. Rubin, MD, professor of Pathology and Laboratory Medicine, vice chairman for Experimental Pathology, director, Translational Research Laboratory Services, Weill Cornell Medicine and New-York Presbyterian, discusses the advantages of whole-exome sequencing and how it compares with targeted sequencing.

Mark A. Schroeder, MD

Latest:

Dr. Schroeder on the Importance of JAK Inhibition in GVHD

Mark A. Schroeder, MD, discusses the importance of JAK inhibition in graft-versus-host disease (GVHD).

Mark A. Socinski

Latest:

Dr. Socinski on the Evolving Paradigm of Targeted Therapy in Lung Cancer

Mark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.

Mark A. Socinski, MD

Latest:

Patient Selection and Sequencing of NSCLC ADCs

The panel examines which patient populations might benefit most from treatment with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd). Additionally, they explore potential sequencing strategies for these antibody-drug conjugates in second-line and later treatment settings.

Mark A. Socinski, MD, Advent Health Cancer Institute

Latest:

NRG1 Fusions in Solid Tumors: The CRESTONE Trial

Dr Mark Socinski describes the design and findings of the CRESTONE trial.

Mark A. Socinski, MD, AdventHealth Cancer Institute

Latest:

Defining Financial Toxicity in Cancer Care

Opening their discussion on the cost of cancer care, expert oncologists define financial toxicity and identify some of its most prevalent contributors.

Mark A. Socinski, MD, Florida Hospital Cancer Institute

Mark A. Socinski, MD, Pittsburgh&nbsp

Mark A. Socinski, MD, University of Pitt